Webseite regulanet.com

Direkte Links und Accesskeys

The International Regulatory Affairs Network

Inhalt

News

02.09.2010  Deng Shuenn Brings An Easy Fitness to Your Life!

"Stay-at-home Economy" is a booming economic activity that focuses on moving, various exercises and physical training without going out. Currently, Deng Shuenn Industrial Co., Ltd has improved the practical efficiency of auxiliary sport equipment, such as the Crazy Fit Massager, Vibration plate training machine and so forth by study from domestic and foreign scholars. It is an alternative choice for those who do not have time for taking exercises, just like white collar workers, SOHO, old-aged and people who find it inconvenient to go outdoors.

More...
02.09.2010  Dr Kevin Johnson Joins Index Ventures as a Partner in the Life Sciences Team

Index Ventures today announced that Dr Kevin Johnson has formally expanded his relationship with the firm and has joined the team as a Partner in the Life Sciences team. Dr Johnson will focus specifically on seeking out new assets in the biologics area, which will enable Index Ventures to build companies based on the asset-centric model he and Index pioneered.

More...
02.09.2010  BRINAVESS™ (Vernakalant) zur Infusion erhält Zulassung in der Europäischen Union für rapide Konversion von kürzlich begonnenem Vorhofflimmern

MSD (in den USA und Kanada unter dem Namen Merck bekannt) (NYSE:MRK) und Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) gaben heute bekannt, dass die intravenös (IV) verabreichte Formulierung von BRINAVESS™ (Vernakalant) die Marktzulassung in der Europäischen Union (EU), Island und Norwegen für die Konversion von kürzlich begonnenem Vorhofflimmern (VHF bzw. AF) in Sinusrhythmus bei erwachsenen Patienten erhalten hat.

More...
02.09.2010  Research and Markets: Examine Norway's Pharmaceutical Market with This Essential Analysis to 2014 As the Market Generated Total Revenues of $2,011.5 Million In 2009

Research and Markets (http://www.researchandmarkets.com/research/ebf598/norway_pharmaceuti) has announced the addition of the "Norway Pharmaceutical Market Analysis, 2010-2014" report to their offering.

More...
02.09.2010  Research and Markets: Daily Updates: Inflammatory Diseases - Tracking Breaking Research, Drug Development News New Trials
More...
02.09.2010  Research and Markets: Trends in Generics Industry Ownership: Evaluating Changing Industry Paradigms and Emerging Players
More...
02.09.2010  Research and Markets: Daily Updates: Cancer Immunotherapy - Tracking Breaking Research, Drug Development News New Trials
More...
02.09.2010  Bohai Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference

Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on Wednesday, September 15, 2010 at 11:40 am Eastern time.

More...
01.09.2010  Lytix Biopharma AS Announces Approval by Hungarian Authorities and Ethics Committee to Start Phase IIa Clinical Trial with LytixarTM (LTX-109) in Gram Positive Skin Infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with LytixarTM (LTX-109) treatment of skin infections caused by Gram positive bacteria.

More...
01.09.2010  Alternative Energy Monthly Deal Analysis and Other Market Research Reports by GlobalData Recently Published at MarketPublishers.com

Market Publishers Ltd informs that new in-demand market reports by GlobalData are available in its catalogue.

More...
01.09.2010  Research and Markets: Health Grants Information Service Identifies Opportunities for Federal, Corporate and Foundation Support of Healthcare

Research and Markets (http://www.researchandmarkets.com/research/bca76e/health_grants_info) has announced the addition of the "Health Grants Information Service" subscription to their offering.

More...
01.09.2010  Research and Markets: Motion Sickness Therapy Area Pipeline Report

Research and Markets (http://www.researchandmarkets.com/research/857fc2/motion_sickness_th) has announced the addition of the "Motion Sickness Therapy Area Pipeline Report" report to their offering.

More...
01.09.2010  Research and Markets: Argentina Pharmaceuticals and Healthcare Report Q4 2010

Research and Markets (http://www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering.

More...
30.08.2010  Covidien Completes Sale of Sleep Therapy Product Line

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced sale of its Sleep Therapy continuous positive airway pressure (CPAP) and Bi-level products to PH Invest, a privately held company located in Luxembourg. Financial terms of the transaction were not disclosed.

More...
30.08.2010  Covidien schließt Verkauf der Produktlinie für Schlaftherapien ab

Covidien (NYSE: COV), ein führender weltweiter Anbieter medizinischer Produkte, meldete heute den Abschluss des zuvor angekündigten Verkaufs der Produkte für Schlaftherapien, für kontinuierlichen Atemwegsüberdruck (Continuous Positive Airway Pressure - CPAP) sowie der Bi-Level-Produkte an PH Invest, eine im Privatbesitz stehende Gesellschaft in Luxemburg. Finanzielle Details der Transaktion wurden nicht bekannt gegeben.

More...
30.08.2010  Pluristem's Placenta Derived Cells Chosen by European Commission's Seventh Framework Program (FP7) Study for Treatment of Diastolic Heart Failure (DHF) in Type 2 Diabetic Patients

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that its PLX cell therapy product, derived from human placenta, a non-controversial, non-embryonic, adult stem cell source, was selected as the only cell therapy product candidate to enter into a study seeking treatments for diastolic heart failure (DHF) in the European Commission's Seventh Framework Program (FP7). Pluristem is to receive a grant from the FP7 to cover study related R&D expenses.

More...
30.08.2010  Research and Markets: Target Product Profiles 2010: Physician Insights on Key Attributes: Diabetic Neuropathy

Research and Markets (http://www.researchandmarkets.com/research/9846c1/target_product_pro) has announced the addition of Decision Resources, Inc.'s new report "Target Product Profiles 2010: Physician Insights on Key Attributes: Diabetic Neuropathy" to their offering.

More...
30.08.2010  Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescription Pharma Sector

Research and Markets (http://www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering.

More...
30.08.2010  Research and Markets: This Analysis Examines the Historical and Forecast Performance for Johnson & Johnson in the Ethical Pharmaceutical Sector

Research and Markets (http://www.researchandmarkets.com/research/aabcf1/johnson_johnson) has announced the addition of the "Johnson & Johnson: PharmaVitae Profile" company profile to their offering.

More...
30.08.2010  Research and Markets: This Analysis Examines the Historical and Forecast Performance for Novartis in the Prescription Pharma Sector

Research and Markets (http://www.researchandmarkets.com/research/a9fe9d/novartis_ag_pharm) has announced the addition of the "Novartis AG: PharmaVitae Profile" company profile to their offering.

More...
30.08.2010  Research and Markets: This Analysis Examines the Historical and Forecast Performance for GlaxoSmithKline in the Prescription Pharmaceutical Sector

Research and Markets (http://www.researchandmarkets.com/research/ac67d7/glaxosmithkline_pl) has announced the addition of the "GlaxoSmithKline plc: PharmaVitae Profile" company profile to their offering.

More...
30.08.2010  Research and Markets: This Essential Report Highlights the Indian Pharmaceutical Sector In Terms Of Market Share, Key Trends, Market Players and Competitive Scenario in the Market

Research and Markets (http://www.researchandmarkets.com/research/d8a430/india_pharmaceutic) has announced the addition of the "India Pharmaceutical Market Analysis, 2010-2014" report to their offering.

More...
30.08.2010  Research and Markets: This Report Highlights Japan's Pharmaceutical Sector in Terms of Market Share, Key Trends, Market Players and Competitive Scenario in the Market

Research and Markets (http://www.researchandmarkets.com/research/3ceeca/japan_pharmaceutic) has announced the addition of the "Japan Pharmaceutical Market Analysis, 2010-2014" report to their offering.

More...
30.08.2010  Research and Markets: This Report Highlights Sweden's Pharmaceutical Sector in Terms of Market Share, Key Trends, Market Players and Competitive Scenario in the Market

Research and Markets (http://www.researchandmarkets.com/research/b87073/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceutical Market Analysis, 2010-2014" report to their offering.

More...
30.08.2010  Research and Markets: This Essential Report Highlights the Asia Pacific Pharmaceutical Sector in Terms of Market Share, Key Trends, Market Players and Competitive Scenario in the Market

Research and Markets (http://www.researchandmarkets.com/research/5f5e15/asiapacific_pharm) has announced the addition of the "Asia-Pacific Pharmaceutical Market Analysis, 2010-2014" report to their offering.

More...
30.08.2010  Research and Markets: This Chronic Obstructive Pulmonary Disease Therapy Area Pipeline Report Contains Detailed Information on the Chronic Obstructive Pulmonary Disease Drug Pipeline
More...
30.08.2010  Research and Markets: This Onychomycosis Therapy Area Pipeline Report Contains Detailed Information on the Onychomycosis Drug Pipeline

Research and Markets (http://www.researchandmarkets.com/research/df6207/onychomycosis_ther) has announced the addition of the "Onychomycosis Therapy Area Pipeline Report" report to their offering.

More...
30.08.2010  Maven Semantic: Database of Dermatology Research

Maven Semantic (http://www.mavensemantic.com) announces updates to their Dermatology research database.

More...
30.08.2010  Research and Markets: Argentina Surgical Equipment Market Outlook to 2016

Research and Markets (http://www.researchandmarkets.com/research/60ef74/argentina_surgical) has announced the addition of GlobalData's new report "Argentina Surgical Equipment Market Outlook to 2016" to their offering.

More...
30.08.2010  Research and Markets: Taiwan Surgical Equipment Market Outlook to 2016

Research and Markets (http://www.researchandmarkets.com/research/722116/taiwan_surgical_eq) has announced the addition of GlobalData 's new report "Taiwan Surgical Equipment Market Outlook to 2016" to their offering.

More...
30.08.2010  Research and Markets: The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses
More...
30.08.2010  Research and Markets: Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control Issues
More...
30.08.2010  Research and Markets: In 2014, the Global Health Care Equipment & Supplies Market Is Forecast To Have a Value of $368.5 Billion, an Increase Of 24.2% Since 2009

Research and Markets (http://www.researchandmarkets.com/research/aa6d13/health_care_equipm) has announced the addition of the "Health Care Equipment & Supplies: Global Industry Guide" report to their offering.

More...
30.08.2010  Elan Corporation plc Announces Commencement of Asset Sale Offer to Purchase up to $186,000,000 of 8 7/8% Senior Fixed Rate Notes Due 2013 and Floating Rate Notes Due 2013

Elan Corporation, plc ("Elan") (NYSE: ELN) announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company ("Elan Finance") and Elan Finance Corp. ("Elan Corp" and together with Elan Finance, the "Issuers"), commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"), in accordance with the terms of the indenture governing the 2013 Notes, at a purchase price of 100% of the principal amount thereof, plus accrued and unpaid interest to the date of payment. The offer will expire at 11:59 p.m., New York City time, on September 29, 2010, unless extended, and is expected to close on September 30, 2010.

More...
30.08.2010  Research and Markets: Industry Solutions Guide: Selecting an Ambulatory EHR Vendor in the Healthcare Market (Competitor Focus)
More...

Ergänzende Informationen zum Inhalt

Zum Seitenanfang